Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
Agomab Therapeutics and SpyGlass Pharma raised a total of $350 million through initial public offerings, marking a significant week for biotech stock issuances. Agomab is advancing a second drug for idiopathic pulmonary fibrosis, with early-stage data expected in 2026.
Read full storyGet the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.